Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A
Status:
Recruiting
Trial end date:
2024-06-21
Target enrollment:
Participant gender:
Summary
- To outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration
- To study pharmacokinetic, side effect of low dose Emicizumab